Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Learn what collagen is, why it may or may not have benefits for psoriasis, according to experts, and what the research has found so far.

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...

And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...

A systematic review and meta-analysis finds that weight-loss interventions are associated with decreased psoriasis severity ...

Incorporating weight-loss interventions improved psoriasis severity and quality of life for patients with overweight or obesity, according to a systematic review and meta-analysis.Approximately 80% of ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...

CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...